1. Scrip

Troriluzole Fails First Phase III Test As Biohaven Looks Beyond Migraine

 
• By Mandy Jackson

Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.

Closed up finger on keyboard with word CLINICAL TRIALS
Troriluzole failed in anxiety, but has three other readouts in 2020 and 2021.

Biohaven Pharmaceutical Holding Co. Ltd. is developing multiple drug candidates that it hopes will broaden its portfolio beyond the acute migraine treatment rimegepant, which is up for US Food and Drug Administration approval soon. But after a Phase II/III failure announced on 10 February, the company will not be expanding via the glutamate modulator troriluzole in the general anxiety disorder (GAD) market.

However, troriluzole could give Biohaven other opportunities to add another drug to its commercial portfolio beyond the calcitonin gene-related peptide (CGRP) inhibitor rimegepant and other migraine therapies

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

More from R&D